Vancouver Television · National

Missouri judge approves $7.25B settlement with Bayer resolving thousands of Roundup cancer claims

Missouri judge approves $7.25B settlement with Bayer resolving thousands of Roundup cancer claims

A Missouri judge has approved a settlement requiring Bayer to make payments totalling as much as $7.25 billion to resolve thousands of U.S. Roundup-related cancer claims.

The Story

A Missouri judge has approved a settlement with Bayer that totals as much as $7.25 billion over up to two decades, designed to resolve thousands of U.S. claims from cancer patients who allege the weed killer Roundup should have been linked to cancer warnings.

The nationwide settlement applies to people who already are ill and those who are diagnosed with non-Hodgkin lymphoma in future years.

The agreement provides for annual payments into a special fund for up to 21 years, with individual payout amounts varying based on factors including how the product was used, a claimant’s age at diagnosis and illness severity.

The settlement includes $600 million for attorneys’ fees, according to the court’s approval judgment.

In the written decision granting approval, St. Louis Circuit Judge Timothy Boyer said the average individual payouts are “fair and adequate,” and that the total dollar amount is “among the largest in the history of mass tort personal-injury class action settlements.”

Boyer also said there was a risk Bayer would have filed for bankruptcy protection if the settlement had been rejected.

Bayer denies that Roundup causes cancer, and the company previously changed the formula for its Roundup version sold to residential users.

Bayer CEO Bill Anderson said in a statement that the court-approved settlement is “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.”

The decision could be appealed.

The litigation follows the use of Roundup, which has been used for more than 50 years; Monsanto debuted Roundup weed killer in 1974 with glyphosate as its active ingredient.

Bayer acquired Monsanto in 2018 and faced growing numbers of lawsuits alleging glyphosate causes non-Hodgkin lymphoma, a connection the company continues to contest.

The World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic” in 2015, while the U.S. Environmental Protection Agency determined it is not likely to cause cancer in humans when used as directed.

The Missouri settlement is tied to a wider legal landscape that included a U.S. Supreme Court ruling in June undercutting one central argument in the Roundup lawsuits, limiting state-court claims about warning labels.

In addition to the newly approved deal, Bayer had set aside $16 billion to cover legal costs related to Roundup cases, and the settlement is intended to address most remaining lawsuits and additional cases brought by people exposed to Roundup before the settlement was proposed in February.

Christopher A. Seeger, a court-appointed counsel for cancer patients in the case, said in the approval materials that the order delivers “guaranteed compensation” to Roundup cancer victims who have waited more than a decade for justice.

← More stories